Brokerages Set IQVIA Holdings Inc. (NYSE:IQV) PT at $259.13

Shares of IQVIA Holdings Inc. (NYSE:IQV) have been given an average rating of “Moderate Buy” by the nineteen analysts that are covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $259.13.

IQV has been the subject of a number of research reports. Morgan Stanley reduced their target price on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Deutsche Bank Aktiengesellschaft cut their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Jefferies Financial Group downgraded IQVIA from a “buy” rating to a “hold” rating and cut their price objective for the stock from $266.00 to $242.00 in a report on Wednesday, July 24th. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Finally, UBS Group upped their price target on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd.

IQVIA Stock Down 4.1 %

IQV opened at $202.94 on Tuesday. The stock’s fifty day moving average is $228.86 and its 200-day moving average is $228.77. IQVIA has a one year low of $200.20 and a one year high of $261.73. The company has a market capitalization of $36.83 billion, a PE ratio of 26.63, a P/E/G ratio of 2.20 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 6.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On IQVIA

Several institutional investors and hedge funds have recently added to or reduced their stakes in IQV. Capital Performance Advisors LLP bought a new stake in shares of IQVIA in the 3rd quarter valued at approximately $27,000. Park Place Capital Corp bought a new position in shares of IQVIA during the third quarter valued at $28,000. Versant Capital Management Inc boosted its stake in shares of IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC bought a new position in IQVIA during the 2nd quarter valued at about $27,000. Finally, Itau Unibanco Holding S.A. acquired a new position in IQVIA in the second quarter valued at about $29,000. 89.62% of the stock is currently owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.